Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab Combination Therapy in Previously Untreated CLL

December 7-10, 2019; Orlando, Florida
Combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and safe as frontline therapy in CLL.
Format: Microsoft PowerPoint (.ppt)
File Size: 294 KB
Released: December 9, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

From Clinical Care Options (CCO), download slides reviewing key CAR T-cell therapy considerations for managed care and specialty pharmacy professionals

person default Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 4, 2021

Commentary from Dr. John Leonard on factors he uses to select mantle cell lymphoma therapy, from Clinical Care Options (CCO)

John P. Leonard, MD Released: July 29, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Clinical commentary featuring expert insights on key CLL studies with BTK inhibitors from ASCO and EHA 2021 from Clinical Care Options (CCO)

Anthony Mato, MD, MSCE William G. Wierda, MD, PhD Released: July 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue